Click on headlines below to download research

2023 to be a year of clinical transition
Sareum Holdings | 23/03/2023

Following a tumultuous H123 marked by UK regulatory challenges for SDC-1801, Sareum has pivoted to Australia as a clinical trial destination. With the…

...read more

SDC-1801 trial application refiled in Australia
Sareum Holdings | 15/03/2023

Following the protracted stalemate with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its clinical trial authorisation (CTA) for…

...read more

SDC-1801 CTA application hits a roadblock
Sareum Holdings | 09/11/2022

Sareum has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has turned down the clinical trial authorisation (CTA) for…

...read more